These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 30939349)
1. Structural optimization on a virtual screening hit of smoothened receptor. Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349 [TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays. Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224 [TBL] [Abstract][Full Text] [Related]
4. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Zhang H; Sun Z; Liu Z; Song C Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists. Ma H; Lu W; Sun Z; Luo L; Geng D; Yang Z; Li E; Zheng J; Wang M; Zhang H; Yang S; Zhang X Eur J Med Chem; 2015 Jan; 89():721-32. PubMed ID: 25462278 [TBL] [Abstract][Full Text] [Related]
6. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers. Li QR; Zhao H; Zhang XS; Lang H; Yu K Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201 [TBL] [Abstract][Full Text] [Related]
7. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant. Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104 [TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant. Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820 [TBL] [Abstract][Full Text] [Related]
10. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity. Sinha N; Chowdhury S; Sarkar RR Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795 [TBL] [Abstract][Full Text] [Related]
11. A novel hedgehog inhibitor for the treatment of hematological malignancies. Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753 [TBL] [Abstract][Full Text] [Related]
12. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo. Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258 [TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Smoothened Ligands Using Structure-Based Docking. Lacroix C; Fish I; Torosyan H; Parathaman P; Irwin JJ; Shoichet BK; Angers S PLoS One; 2016; 11(8):e0160365. PubMed ID: 27490099 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors. Bhattarai D; Jung JH; Han S; Lee H; Oh SJ; Ko HW; Lee K Eur J Med Chem; 2017 Jan; 125():1036-1050. PubMed ID: 27810591 [TBL] [Abstract][Full Text] [Related]
15. New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer. Espinosa-Bustos C; Bertrand J; Villegas-Menares A; Guerrero S; Di Marcotullio L; Navacci S; Schulte G; Kozielewicz P; Bloch N; Villela V; Paulino M; Kogan MJ; Cantero J; Salas CO Bioorg Chem; 2024 Oct; 151():107681. PubMed ID: 39106711 [TBL] [Abstract][Full Text] [Related]
16. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors. Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174 [TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452 [TBL] [Abstract][Full Text] [Related]
19. Evidence for allosteric interactions of antagonist binding to the smoothened receptor. Rominger CM; Bee WL; Copeland RA; Davenport EA; Gilmartin A; Gontarek R; Hornberger KR; Kallal LA; Lai Z; Lawrie K; Lu Q; McMillan L; Truong M; Tummino PJ; Turunen B; Will M; Zuercher WJ; Rominger DH J Pharmacol Exp Ther; 2009 Jun; 329(3):995-1005. PubMed ID: 19304771 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Smo Activity of Some Novel Benzamide Derivatives. Ding H; Chen K; Song B; Deng C; Li W; Niu L; Bai M; Song H; Zhang L Molecules; 2017 Dec; 23(1):. PubMed ID: 29301237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]